Physician profile
Srinivas Seela
NPI 1154385946
$4,485.39
in general payments reported to CMS, 2019-2025
36 companies · $1,104 in 2025
The $1,104 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $318 · 2020: $144 · 2021: $393 · 2022: $582 · 2023: $1,085 · 2024: $860 · 2025: $1,104.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,049.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,048.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,435.36 | 2019-2025 | Rinvoq, Mavyret, Skyrizi |
| Axonics, INC. | $385.27 | 2022-2024 | Axonics |
| Regeneron Healthcare Solutions, INC. | $369.71 | 2023-2024 | Dupixent |
| Madrigal Pharmaceuticals | $250.04 | 2024-2025 | Rezdiffra, Resmetirom |
| Gilead Sciences, INC. | $223.77 | 2019-2025 | Livdelzi |
| Boston Scientific Corporation | $175.12 | 2019-2025 | Axonics |
| Intercept Pharmaceuticals, INC. | $159.84 | 2020-2021 | |
| Janssen Biotech, INC. | $156.65 | 2020-2025 | Tremfya, Stelara, Remicade |
| Nestle Healthcare Nutrition INC. | $137.69 | 2020-2023 | |
| Redhill Biopharma INC. | $135.70 | 2020-2021 | |
| Celgene Corporation | $97.52 | 2021-2024 | Zeposia |
| E.R. Squibb & Sons, L.L.C. | $94.88 | 2021 | |
| Pfizer INC. | $89.96 | 2023-2024 | |
| Braintree Laboratories, INC. | $85.70 | 2021-2025 | Suflave, Sutab |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $85.57 | 2022-2025 | Xifaxan |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $84.59 | 2023-2025 | |
| Enterra Medical, INC. | $73.70 | 2024-2025 | |
| Aimmune Therapeutics, INC. | $53.73 | 2025 | Zenpep |
| Covidien LP | $50.71 | 2019 | |
| Asd Specialty Healthcare, LLC | $49.79 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $36.08 | 2025 | Entyvio |
| Ferring Pharmaceuticals INC. | $33.81 | 2024-2025 | Rebyota |
| Amgen INC. | $26.86 | 2023 | Amjevita, Avsola |
| Blueprint Medicines Corporation | $23.70 | 2025 | Ayvakit |
| Capsovision, INC. | $21.93 | 2025 | Capsocam Plus |
| Alnylam Pharmaceuticals INC. | $21.78 | 2024 | Givlaari |
| Merck Sharp & Dohme LLC | $21.09 | 2024 | Dificid |
| Organon LLC | $20.31 | 2024 | |
| Medtronic, INC. | $17.47 | 2021 | |
| Fresenius Kabi USA, LLC | $16.76 | 2023 | Idacio |
| Lucid Diagnostics INC. | $16.45 | 2024 | |
| Genentech USA, INC. | $14.65 | 2022 | |
| Allergan, INC. | $11.11 | 2019 | |
| Qol Medical, LLC | $8.09 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Srinivas Seela listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.